NCT06922591View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
PDACPDAC - Pancreatic Ductal AdenocarcinomaNSCLCRAS MutationMTAP DeletionLung CancerPancreatic Cancer MetastaticThoracic Cancer
Interventions
DRUG

TNG462

MTA cooperative PRMT5 inhibitor

DRUG

RMC-9805

RAS(ON) G12D selective covalent inhibitor

DRUG

RMC-6236

RAS(ON) multi-selective inhibitor

Trial Locations (6)

10016

RECRUITING

NYU Langone Health, New York

22031

RECRUITING

NEXT Oncology, Fairfax

68124

RECRUITING

Nebraska Cancer Specialists, Omaha

74039

RECRUITING

NEXT Dallas, Irving

77030

RECRUITING

University of Texas MD Anderson Cancer Center, Houston

02115

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Revolution Medicines, Inc.

INDUSTRY

lead

Tango Therapeutics, Inc.

INDUSTRY